Cargando…

BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane

BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotsopoulos, J, Zhang, S, Akbari, M, Salmena, L, Llacuachaqui, M, Zeligs, M, Sun, P, Narod, S A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183839/
https://www.ncbi.nlm.nih.gov/pubmed/25025957
http://dx.doi.org/10.1038/bjc.2014.391
_version_ 1782337749061206016
author Kotsopoulos, J
Zhang, S
Akbari, M
Salmena, L
Llacuachaqui, M
Zeligs, M
Sun, P
Narod, S A
author_facet Kotsopoulos, J
Zhang, S
Akbari, M
Salmena, L
Llacuachaqui, M
Zeligs, M
Sun, P
Narod, S A
author_sort Kotsopoulos, J
collection PubMed
description BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast cancer cells. This has yet to be demonstrated in vivo. METHODS: We conducted a study to evaluate the ability of oral DIM to upregulate BRCA1 mRNA expression in white blood cells. A total of 18 women were enroled in the study, including 13 BRCA1 mutation carriers who received 300 mg per day of Rx Balance BioResponse DIM for 4–6 weeks (intervention group) and 5 BRCA1 mutation carriers who did not take DIM (control group). BRCA1 mRNA expression was assessed at baseline and at 4–6 weeks by real-time, quantitative PCR and the relative change in BRCA1 mRNA expression (that is, 2(−ΔΔC(T))) was calculated. RESULTS: The relative change in BRCA1 mRNA expression among women in the intervention group achieved borderline significance (P paired t-test=0.05). In the intervention group, BRCA1 mRNA expression increased in 10 of the participants, decreased in 2 and remained unchanged in 1 of the participants following DIM intervention (P sign test=0.02). On average, women in the intervention group experienced a 34% increase in BRCA1 mRNA expression (range −24 to 194%). There was no significant difference in the relative change in BRCA1 mRNA expression among women in the control group (P paired t-test=0.45). CONCLUSIONS: Under the tested conditions, oral DIM was associated with an increase in BRCA1 mRNA expression in women with a BRCA1 mutation. The possibility of mitigating the effect of an inherited deleterious BRCA1 mutation by increasing the physiologic expression of the gene and normalising protein levels represents a clinically important paradigm shift in the prevention strategies available to these high-risk women. Future studies with a larger sample size and higher doses of DIM are warranted.
format Online
Article
Text
id pubmed-4183839
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41838392015-09-23 BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane Kotsopoulos, J Zhang, S Akbari, M Salmena, L Llacuachaqui, M Zeligs, M Sun, P Narod, S A Br J Cancer Clinical Study BACKGROUND: Haploinsufficiency may contribute to the development of breast cancer among women with a BRCA1 mutation. Thus, interventions that enhance BRCA1 expression may represent avenues for prevention. Studies have shown that 3,3′-diindolylmethane (DIM) can upregulate BRCA1 expression in breast cancer cells. This has yet to be demonstrated in vivo. METHODS: We conducted a study to evaluate the ability of oral DIM to upregulate BRCA1 mRNA expression in white blood cells. A total of 18 women were enroled in the study, including 13 BRCA1 mutation carriers who received 300 mg per day of Rx Balance BioResponse DIM for 4–6 weeks (intervention group) and 5 BRCA1 mutation carriers who did not take DIM (control group). BRCA1 mRNA expression was assessed at baseline and at 4–6 weeks by real-time, quantitative PCR and the relative change in BRCA1 mRNA expression (that is, 2(−ΔΔC(T))) was calculated. RESULTS: The relative change in BRCA1 mRNA expression among women in the intervention group achieved borderline significance (P paired t-test=0.05). In the intervention group, BRCA1 mRNA expression increased in 10 of the participants, decreased in 2 and remained unchanged in 1 of the participants following DIM intervention (P sign test=0.02). On average, women in the intervention group experienced a 34% increase in BRCA1 mRNA expression (range −24 to 194%). There was no significant difference in the relative change in BRCA1 mRNA expression among women in the control group (P paired t-test=0.45). CONCLUSIONS: Under the tested conditions, oral DIM was associated with an increase in BRCA1 mRNA expression in women with a BRCA1 mutation. The possibility of mitigating the effect of an inherited deleterious BRCA1 mutation by increasing the physiologic expression of the gene and normalising protein levels represents a clinically important paradigm shift in the prevention strategies available to these high-risk women. Future studies with a larger sample size and higher doses of DIM are warranted. Nature Publishing Group 2014-09-23 2014-07-15 /pmc/articles/PMC4183839/ /pubmed/25025957 http://dx.doi.org/10.1038/bjc.2014.391 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Kotsopoulos, J
Zhang, S
Akbari, M
Salmena, L
Llacuachaqui, M
Zeligs, M
Sun, P
Narod, S A
BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title_full BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title_fullStr BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title_full_unstemmed BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title_short BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
title_sort brca1 mrna levels following a 4–6-week intervention with oral 3,3′-diindolylmethane
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183839/
https://www.ncbi.nlm.nih.gov/pubmed/25025957
http://dx.doi.org/10.1038/bjc.2014.391
work_keys_str_mv AT kotsopoulosj brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT zhangs brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT akbarim brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT salmenal brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT llacuachaquim brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT zeligsm brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT sunp brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane
AT narodsa brca1mrnalevelsfollowinga46weekinterventionwithoral33diindolylmethane